Tempus AI (NASDAQ:TEM) Given “Buy” Rating at BTIG Research

Tempus AI (NASDAQ:TEM)‘s stock had its “buy” rating reiterated by BTIG Research in a note issued to investors on Monday, Benzinga reports. They presently have a $80.00 price target on the stock. BTIG Research‘s target price would suggest a potential upside of 19.64% from the stock’s current price.

Other equities research analysts have also recently issued reports about the company. Wall Street Zen upgraded Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. Guggenheim upped their target price on Tempus AI from $65.00 to $92.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. UBS Group began coverage on Tempus AI in a report on Wednesday, September 9th. They issued a “neutral” rating and a $70.00 target price for the company. HC Wainwright boosted their price target on Tempus AI from $66.00 to $68.00 and gave the stock a “buy” rating in a research report on Monday. Finally, TD Cowen reissued a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. Eleven analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Tempus AI has a consensus rating of “Hold” and an average price target of $72.47.

Tempus AI Trading Down 1.1%

Shares of TEM stock traded down $0.74 on Monday, reaching $66.87. 1,345,093 shares of the company’s stock were exchanged, compared to its average volume of 6,165,884. Tempus AI has a 52 week low of $40.77 and a 52 week high of $93.38. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The stock has a market capitalization of $12.07 billion, a PE ratio of -46.73 and a beta of 3.54. The company’s fifty day simple moving average is $69.24 and its 200 day simple moving average is $57.26.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%. The business had revenue of $382.49 million during the quarter, compared to analysts’ expectations of $379.69 million. During the same period in the prior year, the business earned ($0.22) EPS. The business’s revenue for the quarter was up 21.6% compared to the same quarter last year. As a group, analysts forecast that Tempus AI will post -1.43 EPS for the current year.

Insider Buying and Selling

In related news, CEO Eric P. Lefkofsky sold 250,000 shares of the business’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $42.06, for a total transaction of $10,515,000.00. Following the transaction, the chief executive officer directly owned 200,000 shares in the company, valued at $8,412,000. The trade was a 55.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ryan Fukushima sold 41,095 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total value of $2,038,722.95. Following the transaction, the chief executive officer owned 562,463 shares in the company, valued at approximately $27,903,789.43. This trade represents a 6.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 1,280,965 shares of company stock valued at $80,397,564. 24.26% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Eagle Health Investments LP purchased a new position in Tempus AI during the 1st quarter worth $11,588,000. Aristotle Atlantic Partners LLC purchased a new position in Tempus AI during the 1st quarter worth $6,179,000. Headlands Technologies LLC purchased a new stake in Tempus AI during the 2nd quarter valued at about $2,689,000. Odyssean LLC purchased a new stake in Tempus AI during the 2nd quarter valued at about $897,000. Finally, Canal Insurance CO grew its stake in Tempus AI by 100.0% during the 1st quarter. Canal Insurance CO now owns 40,000 shares of the company’s stock valued at $1,809,000 after purchasing an additional 20,000 shares during the last quarter. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.